Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa + pegylated interferon alfa
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Interferon alfa refers to a family of recombinant or naturally occurring cytokines with antiviral and immunomodulatory properties. Pegylated interferon alfa (peginterferon alfa) is a modified form in which polyethylene glycol (PEG) is covalently attached to the interferon molecule. This modification extends the half-life and allows for less frequent dosing compared to conventional (non-pegylated) interferons. Both forms act by binding to type 1 human interferon receptors on cell surfaces, activating the JAK/STAT signaling pathway and inducing expression of genes involved in antiviral defense and immune regulation. These drugs have been foundational therapies for chronic hepatitis C virus (HCV) infection—often in combination with ribavirin—and are also used for chronic hepatitis B virus infection[1][2][3][8]. The introduction of direct acting antivirals has reduced their use as first-line therapy.
- Brand names
- Pegasys ProClick AutoinjectorPegasys Prefilled Syringe
- Other names
- IFN-alphaPEG-IFN-alpha
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon alfa + pegylated interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa + pegylated interferon alfa.